pan-phosphoinositide 3-kinase

临床试验

计划入组 30 人 · 首次发布于 2017 年 12 月 26 日

招募中

NCT06694363

New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome

计划入组 14 人 · 首次发布于 2024 年 11 月 19 日

终止

NCT03178201

TGR1202 in Relapsed and Refractory Follicular Lymphoma

计划入组 5 人 · 首次发布于 2017 年 6 月 6 日

药物

查看全部 5534 →

KIT-2014

Small Molecule

Approved

Leniolisib(Joenja)

相关疾病：Activated PI3 kinase delta syndrome

C₂₁H₂₅F₃N₆O₂

pan-Pim kinase inhibitors (Amgen)

机构

查看全部 1528 →

Tai Pan Vacation Inc.

Canada

3-D Matrix Ltd.

Japan

River 3 Renal Corp.

United States

资讯

查看全部 14145 →

去年

Adlai Nortye's AN2025 Shows Promise in Head and Neck Cancer Treatment

去年

Pharming Group Initiates Phase II Trial of Leniolisib for Primary Immunodeficiencies

去年

临床试验

Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome

New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome

TGR1202 in Relapsed and Refractory Follicular Lymphoma

药物

KIT-2014

Leniolisib(Joenja)

pan-Pim kinase inhibitors (Amgen)

机构

Tai Pan Vacation Inc.

3-D Matrix Ltd.

River 3 Renal Corp.

资讯

Adlai Nortye's AN2025 Shows Promise in Head and Neck Cancer Treatment

Pharming Group Initiates Phase II Trial of Leniolisib for Primary Immunodeficiencies

Adlai Nortye's Buparlisib Poised to Potentially Be First PI3K Inhibitor for Head and Neck Cancer